Streetbeat News

Products Services

MNMD

Mind Medicine (MindMed) (NASDAQ:MNMD) has reported its Q3 2023 financial results, showing a 17.2% decrease in cash and cash equivalents from the end of 2022, but a mild 0.6% increase from Q2 2023. The company's R&D expenses increased by 69.2% YoY, while G&A expenses decreased by 8.7%. MindMed's net loss for the quarter was $17.9 million, an 8.5% increase from the same period in 2022. The company believes its current cash and committed credit facility will fund operations into 2026, if certain milestones are achieved. Key upcoming milestones include the results of Phase 2b and Phase 2 studies on LSD molecule MM-120 for adults with Generalized Anxiety Disorder and ADHD, respectively, and a Phase 1 study of MM-402 targeting Autism Spectrum Disorder.

Portfolio Pulse from Lara Goldstein

November 03, 2023 | 6:12 pm

NIO

Nio Inc's shares rose by 5.5% due to the company's recent delivery update and positive market sentiment following the Federal Reserve's decision. NIO reported a 59.8% YoY increase in October 2023 deliveries, reaching a cumulative delivery milestone of 415,623 vehicles. The company's ET5T received a five-star safety rating from Euro NCAP and has expanded its charging infrastructure.

Portfolio Pulse from Henry Khederian

November 03, 2023 | 5:52 pm

SIEGY

Siemens AG (OTC:SIEGY) plans to invest over $500 million in the U.S. manufacturing sector, including a $150 million high-tech manufacturing plant in Dallas-Fort Worth, Texas, to support American data centers and critical infrastructure. The company also plans to invest in a new rail manufacturing facility in Lexington, North Carolina, and two electrical-products manufacturing plants in Texas and California. These investments are expected to create 1,700 jobs and are part of Siemens' €2 billion global investment strategy for 2023.

Portfolio Pulse from Shivani Kumaresan

November 03, 2023 | 5:42 pm

BNOX

Bionomics has been granted a European patent EP3867252 for its 6-INDAN-2-YLOXY-3-(MORPHOLINE-4-CARBONYL)-1,8-NAPHTHYRIDIN-4-ONE derivatives and similar compounds. These compounds are modulators of the Alpha 7 Nicotinic Acetylcholine Receptor and are used for the treatment of anxiety.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 5:41 pm

TSLA

A video has surfaced showing Tesla Inc's Cybertruck frunk opening on its own, suggesting it might be powered. This is the first time Tesla has included a powered frunk on any vehicle, and it is also paired with a new button to open the frunk from the outside.

Portfolio Pulse from Benzinga EV Insights

November 03, 2023 | 5:24 pm

SPCE

Virgin Galactic Holdings Inc (NASDAQ:SPCE) shares are trading higher by 9.4% after the company announced the completion of its sixth space mission in six months and its tenth mission overall. The recent mission involved converting Virgin Galactic's spaceship into a suborbital lab for space-based scientific research. The company plans to proceed with post-flight analysis and pre-flight readiness procedures for its next commercial space mission, scheduled for January next year.

Portfolio Pulse from Henry Khederian

November 03, 2023 | 5:10 pm

NIO

Chinese electric vehicle manufacturer Nio plans to sell its first car in the U.S. by 2025 as part of its expansion strategy to 25 countries and regions. Instead of setting up local production to qualify for tax incentives, Nio will import premium electric cars made in China to the U.S.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:58 pm

AMZN

NFLX

PARA

Netflix Inc is reportedly exploring the possibility of entering the live sports streaming market with a potential boxing match. Discussions are underway about live-streaming a match involving Jake Paul. There are also talks about featuring bouts from Premier Boxing Champions, a series currently aired on Paramount's Showtime. Paramount Global's decision to shutter Showtime Sports has created an opportunity for platforms like Netflix and Amazon.com to consider hosting Premier Boxing Champions matches.

Portfolio Pulse from Vandana Singh

November 03, 2023 | 4:52 pm

MDNA

Medicenna Therapeutics Corp. (TSX:MDNA) presented new preclinical data on its T-MASK platform and MDNA113, a first-in-class IL-13R⍺2 targeted therapy, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The data shows the platform's ability to enhance tumor specific accumulation, increase anti-tumor activity, and improve the safety profile of immune modulators. MDNA113 is designed to deliver bispecific IL-2-antiPD1 Superkine to cancers that express the tumor associate antigen, IL-13R⍺2, which is linked to aggressive cancers affecting over 2 million patients annually.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:13 pm

INAB

IN8bio, Inc. (NASDAQ:INAB) presented new positive preclinical data from its induced pluripotent stem cell (iPSC) gamma-delta T cell platform at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting. The data represents a significant advance in the development of the INB-500 iPSC program towards the development of allogeneic gamma-delta T cell therapies. The company's proprietary process can be scaled for full GMP manufacturing, and the iPSC-derived gamma-delta T cells have shown strong cancer-killing abilities against various solid and liquid cancers.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:12 pm